WO2003038441A2 - Procedes de criblage a base de proteines de la famille des cited - Google Patents

Procedes de criblage a base de proteines de la famille des cited Download PDF

Info

Publication number
WO2003038441A2
WO2003038441A2 PCT/GB2002/004997 GB0204997W WO03038441A2 WO 2003038441 A2 WO2003038441 A2 WO 2003038441A2 GB 0204997 W GB0204997 W GB 0204997W WO 03038441 A2 WO03038441 A2 WO 03038441A2
Authority
WO
WIPO (PCT)
Prior art keywords
protein
cited
tfap2
amino acid
cbp
Prior art date
Application number
PCT/GB2002/004997
Other languages
English (en)
Other versions
WO2003038441A3 (fr
Inventor
Jose Braganca
Fatima Marques
Shoumo Bhattacharya
Simon Bamforth
Helen Catherine Hurst
Jyrki Johannes Eloranta
Original Assignee
Isis Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation Ltd filed Critical Isis Innovation Ltd
Publication of WO2003038441A2 publication Critical patent/WO2003038441A2/fr
Publication of WO2003038441A3 publication Critical patent/WO2003038441A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

La présente invention concerne un procédé permettant d'identifier in vitro des composés bloquant l'interaction entre une protéine de la famille des CITED et une protéine TFAP2, ces composés présentant ainsi une activité potentielle pour le traitement du cancer. A cet effet, on commence par réaliser un mélange entre un premier composant à base de protéines dont une protéine CITED, un second composant à base de protéines dont une protéine TFAP2, et un candidat composé. On met à incuber le mélange dans des conditions qui, en l'absence du candidat composé, permettraient la liaison de la protéine CITED à la protéine TFAP2. Il ne reste plus qu'à détecter les éventuelles liaisons de la protéine CITED à la protéine TFAP2. En l'occurrence, les composés qui bloquent la liaison de la protéine CITED à la protéine TFAP2 sont identifiés comme présentant une activité pharmacologique potentielle dans le traitement du cancer du sein.
PCT/GB2002/004997 2001-11-02 2002-11-04 Procedes de criblage a base de proteines de la famille des cited WO2003038441A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0126386.2 2001-11-02
GB0126386A GB0126386D0 (en) 2001-11-02 2001-11-02 Screening methods based on cited family proteins

Publications (2)

Publication Number Publication Date
WO2003038441A2 true WO2003038441A2 (fr) 2003-05-08
WO2003038441A3 WO2003038441A3 (fr) 2004-03-11

Family

ID=9925062

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004997 WO2003038441A2 (fr) 2001-11-02 2002-11-04 Procedes de criblage a base de proteines de la famille des cited

Country Status (2)

Country Link
GB (1) GB0126386D0 (fr)
WO (1) WO2003038441A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1793003A1 (fr) * 2005-11-30 2007-06-06 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts CITED4 en tant que marqueur de pronostic pour les tumeurs oligodendrogliales
JP2007275052A (ja) * 2006-03-17 2007-10-25 Hironobu Yanagimori ＴＢＣＥ遺伝子またはＣＩＴＥＤ２遺伝子に特異的なｓｉＲＮＡおよびその用途
US20130011422A1 (en) * 2003-05-16 2013-01-10 Neil Berinstein Tumor Antigens for the Prevention and/or Treatment of Cancer
US20200247861A1 (en) * 2012-04-02 2020-08-06 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068846A2 (fr) * 2000-03-17 2001-09-20 Isis Innovation Limited Proteine transactivatrice transcriptionnelle
WO2003000730A1 (fr) * 2001-06-21 2003-01-03 The General Hospital Corporation Composes qui modulent les actions oestrogeniques

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001068846A2 (fr) * 2000-03-17 2001-09-20 Isis Innovation Limited Proteine transactivatrice transcriptionnelle
WO2003000730A1 (fr) * 2001-06-21 2003-01-03 The General Hospital Corporation Composes qui modulent les actions oestrogeniques

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BRAGANCA J ET AL: "Human CREB-binding protein/p300-interacting transactivator with ED-rich tail (CITED) 4, a new member of the CITED family, functions as a co-activator for transcription factor AP-2" JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 277, no. 10, 8 March 2002 (2002-03-08), pages 8559-8565, XP002956485 ISSN: 0021-9258 *
YAHATA TETSURO ET AL: "The MSG1 non-DNA-binding transactivator binds to the p300/CBP coactivators, enhancing their functional link to the Smad transcription factors" JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, no. 12, 24 March 2000 (2000-03-24), pages 8825-8834, XP002260912 ISSN: 0021-9258 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130011422A1 (en) * 2003-05-16 2013-01-10 Neil Berinstein Tumor Antigens for the Prevention and/or Treatment of Cancer
EP1793003A1 (fr) * 2005-11-30 2007-06-06 Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts CITED4 en tant que marqueur de pronostic pour les tumeurs oligodendrogliales
WO2007062827A1 (fr) * 2005-11-30 2007-06-07 Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Cited4 en tant que marqueur de pronostic dans des tumeurs oligodendrogliales
JP2007275052A (ja) * 2006-03-17 2007-10-25 Hironobu Yanagimori ＴＢＣＥ遺伝子またはＣＩＴＥＤ２遺伝子に特異的なｓｉＲＮＡおよびその用途
US20200247861A1 (en) * 2012-04-02 2020-08-06 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides

Also Published As

Publication number Publication date
GB0126386D0 (en) 2002-01-02
WO2003038441A3 (fr) 2004-03-11

Similar Documents

Publication Publication Date Title
US7709600B2 (en) Interaction between the VHL tumor suppressor and hypoxia inducible factor, and assay methods relating thereto
JP3633616B2 (ja) 転写因子ｄｐ−１
US7303885B1 (en) Screening method for candidate drugs
US20040224408A1 (en) THAP proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
KR100766952B1 (ko) 조절성 징크 핑거 단백질
EP1141005B1 (fr) Methodes d'identification de modulateurs du facteur inductible par l'hypoxie hif-1alpha
WO2003057204A2 (fr) Prevention ou attenuation de l'auto-immunite
US5905146A (en) DNA binding protein S1-3
WO2000075184A9 (fr) Modulation de taux de proteines au moyen du complexe scf
EP1263951A2 (fr) Proteine transactivatrice transcriptionnelle
WO2003038441A2 (fr) Procedes de criblage a base de proteines de la famille des cited
Komatsuzaki et al. Modulation of Giα2 signaling by the axonal guidance molecule UNC5H2
Bruce et al. Activation of heat shock transcription factor 1 to a DNA binding form during the G1phase of the cell cycle
EP1544295A1 (fr) Kinases 2 induites par des sels et leur utilisation
US20070099215A1 (en) NOVEL Bak BINDING PROTEIN, DNA ENCODING THE PROTEIN, AND METHODS OF USE THEREOF
US7053194B2 (en) Compositions and methods for p53-mediated repression of gene expression
US8889408B2 (en) Factor taking part in transcription control
MXPA05010312A (es) Proteinas activadoras de elementos de respuesta de amp ciclico y usos relacionados a ellas.
CA2801162A1 (fr) Applications de diagnostic, de depistage et therapeutiques d'outils a base de la proteine ocab
US9074202B2 (en) Method of inhibiting human Trabid
WO2006007375A2 (fr) Utilisation de bridge-1 et activateurs et inhibiteurs de ceux-ci utilises dans le traitement du diabete insulino-dependant
US7160677B1 (en) Transcription factor DP-1
WO2005052150A1 (fr) Procede pour reguler la transcription du gene de l'insuline
Lele Transcriptional control of the gene for cyclin A1 and kinetic analysis of mutant cyclin A1/CDK complexes associated with infertility
Bragança et al. Human CITED4, a new member of the CBP/p300 Interacting Transactivator with ED-rich tail family, functions as a co-activator for transcription factor AP-2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase in:

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP